TOMI Environmental Solutions Positioned to Address Growing Global Disease Threats with SteraMist Technology
TOMI Environmental Solutions (NASDAQ: TOMZ) announces its readiness to address emerging public health threats using its SteraMist technology amid growing concerns over RSV, HMPV, and H5N1 viruses. The company is expanding its reach to government agencies, commercial clients, and school districts nationwide.
Building on its track record in controlling previous pandemics like Ebola and SARS-CoV-2, TOMI is positioned to meet increasing demand for infection prevention solutions. The company secured new contracts with school districts and is collaborating with distributors as global infectious disease threats intensify, including the HMPV surge in China and ongoing avian flu outbreak.
With the U.S. Department of Health and Human Services allocating $306 million for avian flu response, TOMI's technology is well-suited for high-risk environments. The company's SteraMist solution, which uses ionized Hydrogen Peroxide technology, leaves no harmful residues and is environmentally friendly, making it suitable for various applications including healthcare facilities, schools, and food production facilities.
TOMI Environmental Solutions (NASDAQ: TOMZ) annuncia la sua prontezza a fronteggiare le crescenti minacce per la salute pubblica utilizzando la sua tecnologia SteraMist, in mezzo a crescenti preoccupazioni per i virus RSV, HMPV e H5N1. L'azienda sta espandendo la sua presenza verso agenzie governative, clienti commerciali e distretti scolastici a livello nazionale.
Basandosi sulla sua esperienza nel controllo di precedenti pandemie come Ebola e SARS-CoV-2, TOMI è ben posizionata per soddisfare la crescente domanda di soluzioni per la prevenzione delle infezioni. L'azienda ha ottenuto nuovi contratti con distretti scolastici e sta collaborando con distributori mentre le minacce globali di malattie infettive si intensificano, inclusa l'aumento di HMPV in Cina e l'attuale focolaio di influenza aviaria.
Con il Dipartimento della Salute e dei Servizi Umani degli Stati Uniti che destina 306 milioni di dollari per la risposta all'influenza aviaria, la tecnologia di TOMI è ben adatta per ambienti ad alto rischio. La soluzione SteraMist dell'azienda, che utilizza la tecnologia dell'ossigeno attivato ionizzato, non lascia residui nocivi ed è ecocompatibile, rendendola adatta a diverse applicazioni, compresi gli ospedali, le scuole e le strutture di produzione alimentare.
TOMI Environmental Solutions (NASDAQ: TOMZ) anuncia su disposición para abordar las crecientes amenazas a la salud pública utilizando su tecnología SteraMist en medio de la creciente preocupación por los virus RSV, HMPV y H5N1. La empresa está ampliando su alcance a agencias gubernamentales, clientes comerciales y distritos escolares en todo el país.
Aprovechando su trayectoria en el control de pandemias anteriores como el Ébola y el SARS-CoV-2, TOMI está posicionada para satisfacer la creciente demanda de soluciones para la prevención de infecciones. La empresa ha asegurado nuevos contratos con distritos escolares y está colaborando con distribuidores mientras las amenazas globales de enfermedades infecciosas se intensifican, incluida la ola de HMPV en China y el brote de gripe aviar que continúa.
Con el Departamento de Salud y Servicios Humanos de EE. UU. asignando 306 millones de dólares para la respuesta a la gripe aviar, la tecnología de TOMI es adecuada para entornos de alto riesgo. La solución SteraMist de la compañía, que utiliza tecnología de Peróxido de Hidrógeno ionizado, no deja residuos nocivos y es respetuosa con el medio ambiente, lo que la hace adecuada para diversas aplicaciones, incluidos los centros de salud, las escuelas y las instalaciones de producción de alimentos.
TOMI Environmental Solutions (NASDAQ: TOMZ)는 RSV, HMPV 및 H5N1 바이러스에 대한 우려가 커짐에 따라 SteraMist 기술을 사용하여 대두되는 공공 건강 위협에 대응할 준비가 되었다고 발표했습니다. 이 회사는 전국의 정부 기관, 상업 고객 및 학군으로의 접근을 확장하고 있습니다.
Ebola 및 SARS-CoV-2와 같은 이전 팬데믹을 통제한 경험을 바탕으로 TOMI는 감염 예방 솔루션에 대한 증가하는 수요를 충족할 수 있는 위치에 있습니다. 이 회사는 학군과의 새로운 계약을 체결하였으며, 글로벌 전염병 위협이 강화됨에 따라 유통업체와 협력하고 있습니다. 여기에는 중국의 HMPV 급증과 지속되는 조류 독감 발병이 포함됩니다.
미국 보건복지부가 조류 독감 대응을 위해 3억 6만 달러를 배정함에 따라 TOMI의 기술은 고위험 환경에 적합합니다. 회사의 SteraMist 솔루션은 이온화된 과산화수소 기술을 사용하며 유해 잔여물이 남지 않으며 환경 친화적이어서 의료 시설, 학교 및 식품 생산 시설 등 다양한 용도로 적합합니다.
TOMI Environmental Solutions (NASDAQ: TOMZ) annonce sa capacité à répondre aux menaces émergentes pour la santé publique en utilisant sa technologie SteraMist au milieu des préoccupations croissantes concernant les virus RSV, HMPV et H5N1. L'entreprise élargit son domaine d'intervention aux agences gouvernementales, aux clients commerciaux et aux districts scolaires à l'échelle nationale.
S'appuyant sur son expérience dans la gestion des pandémies précédentes comme Ebola et le SARS-CoV-2, TOMI est bien positionnée pour répondre à une demande croissante de solutions de prévention des infections. L'entreprise a sécurisé de nouveaux contrats avec des districts scolaires et collabore avec des distributeurs alors que les menaces mondiales de maladies infectieuses s'intensifient, y compris l'augmentation des cas de HMPV en Chine et l'épidémie de grippe aviaire qui se poursuit.
Avec le Département de la Santé et des Services sociaux des États-Unis allouant 306 millions de dollars à la réponse à la grippe aviaire, la technologie de TOMI est bien adaptée aux environnements à haut risque. La solution SteraMist de l'entreprise, qui utilise la technologie du peroxyde d'hydrogène ionisé, ne laisse aucun résidu nocif et est respectueuse de l'environnement, ce qui la rend adaptée à diverses applications, y compris les établissements de santé, les écoles et les installations de production alimentaire.
TOMI Environmental Solutions (NASDAQ: TOMZ) kündigt seine Bereitschaft an, auf zunehmende Bedrohungen der öffentlichen Gesundheit mit seiner SteraMist-Technologie zu reagieren, während die Bedenken bezüglich RSV, HMPV und H5N1-Viren wachsen. Das Unternehmen erweitert seine Reichweite auf Regierungsbehörden, kommerzielle Kunden und Schulbezirke im ganzen Land.
Aufbauend auf seinen Erfolgen bei der Bekämpfung früherer Pandemien wie Ebola und SARS-CoV-2 ist TOMI gut positioniert, um der steigenden Nachfrage nach Infektionsschutzlösungen gerecht zu werden. Das Unternehmen sicherte sich neue Verträge mit Schulbezirken und arbeitet mit Vertriebspartnern zusammen, während die globalen Bedrohungen durch Infektionskrankheiten zunehmen, darunter der HMPV-Anstieg in China und der anhaltende Ausbruch der Vogelgrippe.
Da das US-Gesundheitsministerium 306 Millionen Dollar für die Bekämpfung der Vogelgrippe bereitstellt, ist die Technologie von TOMI bestens geeignet für hochriskante Umgebungen. Die SteraMist-Lösung des Unternehmens, die auf ionisierter Wasserstoffperoxid-Technologie basiert, hinterlässt keine schädlichen Rückstände und ist umweltfreundlich, wodurch sie für verschiedene Anwendungen geeignet ist, einschließlich Gesundheitsversorgung, Schulen und Lebensmittelproduktionsstätten.
- Secured new contracts with school districts
- Positioned to benefit from $306 million HHS funding for avian flu response
- Expanding market reach across government, commercial, and education sectors
- Proven track record in pandemic response (Ebola, SARS-CoV-2)
- None.
Insights
This announcement represents a strategic positioning rather than material business development. While TOMI highlights potential opportunities in emerging disease threats and mentions new school district contracts, no specific financial details, contract values, or revenue projections are provided. The $306 million HHS funding for avian flu response represents a broader market opportunity rather than secured business.
The microcap company (
The reference to past successes with Ebola and SARS-CoV-2 provides historical context but doesn't translate to guaranteed future performance. Investors should note that while the addressable market may be expanding, the company's ability to capture significant market share remains to be proven through tangible financial results.
The SteraMist technology's competitive advantages - including no harmful residues and environmental friendliness - are noteworthy technical features, but the announcement lacks specifics about market penetration or adoption rates. The Binary Ionization Technology (BIT) platform's DARPA origins lend credibility, but the commercial success of this technology needs to be demonstrated through concrete sales figures and growth metrics.
In simple terms: Think of TOMI as having a powerful tool in their toolkit, but we still need to see how many customers are actually buying and using it. The company's positioning in multiple sectors (healthcare, education, food production) shows potential for diversified revenue streams, but without specific financial details or major contract announcements, this remains more about potential than current impact.
The mention of school district partnerships is promising but requires quantification in terms of contract values and implementation timelines to assess real business impact. The current announcement serves more as a capability statement rather than a material business development.
Company Expands Reach to Government, Commercial Entities, and School Districts Amid Rising Concerns Over Spread of Respiratory Viruses such as RSV, HMPV, and H5N1
FREDERICK, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that the Company is supporting partners and clients preparing for emerging public health threats as concerns grow over Respiratory Syncytial Virus (RSV), Human Metapneumovirus (HMPV), and the highly pathogenic Avian Influenza (H5N1). TOMI is leveraging its SteraMist technology to provide innovative infection prevention strategies essential to safeguard the health of government agencies, commercial clients, and school districts nationwide.
Building on its success in controlling past pandemics, including Ebola and SARS-CoV-2, TOMI is well-positioned to meet the urgent demand for effective infection prevention solutions in high-risk environments. Recent new contracts with school districts highlight TOMI’s expanding footprint in critical sectors as institutions enhance their preparedness for rising disease threats.
TOMI has been collaborating with distributors and customers as global infectious disease threats continue to intensify, including the recent surge of HMPV in China and the ongoing avian flu outbreak. HMPV, linked to severe illness in vulnerable populations, is highly contagious, spreading through respiratory droplets and contaminated surfaces. Similarly, H5N1 poses the risk of zoonotic and potential human-to-human transmission with the first human death recorded in Louisiana. With funding allocated by the U.S. Department of Health and Human Services (HHS) for pandemic preparedness, including
“Preparedness is the key to protecting public health and ensuring the safety of our communities," said Dr. Halden Shane, CEO of TOMI Environmental Solutions. “As global disease risks grow, SteraMist technology offers unmatched disinfection capabilities, ensuring rapid, effective decontamination across diverse settings. From hospitals to schools and government facilities, our solutions are uniquely designed to mitigate the spread of infectious diseases like RSV, HMPV, and H5N1 while supporting proactive pandemic response efforts.
“TOMI’s SteraMist leaves no harmful residues and is environmentally friendly. It is ideal for a wide range of applications, including schools, universities, healthcare facilities, transportation systems, food production, and more. TOMI’s partnerships with school districts exemplify its ability to deliver effective infection control solutions to protect students and staff while contributing to public health efforts.”
TOMI Environmental Solutions is committed to supporting healthcare providers and public health officials in their efforts to combat emerging infectious diseases. By leveraging advanced disinfection technologies and promoting a culture of infection prevention and proactive disinfection, we can significantly improve the way the world reacts to the next pandemic.
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit http://www.steramist.com or contact us at info@tomimist.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to the ability of TOMI’s products to address global epidemics and disease threats. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
tomi@imsinvestorrelations.com
FAQ
How is TOMZ positioned to benefit from the $306 million HHS funding for avian flu response?
What new markets is TOMZ expanding into with its SteraMist technology?
What infectious diseases is TOMZ's SteraMist technology targeting?
What are the key features of TOMZ's SteraMist disinfection technology?
What previous pandemic experience does TOMZ have with its disinfection solutions?
